A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Inclusion Criteria:

- Diagnosis of confirmed mantle cell lymphoma (MCL) with at least 1 measurable site of
disease according to Revised Response Criteria for Malignant Lymphoma

- Must have received at least 1 prior rituximab-containing chemotherapy regimen, but no
more than 5 prior regimens

- Must have received at least 2 cycles of bortezomib therapy (single-agent or in
combination) and have documented progressive disease during or after bortezomib
therapy

- Eastern Cooperative Oncology Group performance status score 0, 1, or 2

- Hematology and biochemical values within protocol-defined parameters

Exclusion Criteria:

- Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic
anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10
weeks, radiation therapy or other investigational agents within 3 weeks, or major
surgery within 4 weeks of the first dose of study drug

- Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors

- More than 5 prior lines of therapy (separate lines of therapy are defined as single
or combination therapies that are either separated by disease progression or by a >6
month treatment-free interval

- Known central nervous system lymphoma

- Diagnosed or treated for malignancy other than MCL, except malignancy treated with
curative intent and with no known active disease present for >=3 years before the
first dose of study drug and felt to be at low risk for recurrence by the treating
physician, adequately treated non-melanoma skin cancer or lentigo maligna without
evidence of disease, or adequately treated cervical carcinoma in situ without
evidence of disease.

- History of stroke or intracranial hemorrhage within 6 months prior to the first dose
of study drug

- Requires anticoagulation with warfarin or equivalent vitamin K antagonists

- Requires treatment with strong CYP3A4/5 inhibitors

- Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined
by the New York Heart Association Functional Classification

- Known history of human immunodeficiency virus or active infection with hepatitis C
virus or hepatitis B virus or any uncontrolled active systemic infection

- Any life-threatening illness, medical condition, or organ system dysfunction which,
in the investigator's opinion, could compromise the patient's safety, interfere with
the absorption or metabolism of ibrutinib capsules, or put the study outcomes at
undue risk